Novel Agents in the Treatment of Lung Cancer: Advances in EGFR-targeted Agents
Third Cambridge Conference - September 2005
This multidisciplinary CME program was directed by Dr. Thomas Lynch, Massachusetts General Hospital. The educational objectives for the program were to review new information on lung cancer biology and EGFR biology as they pertain to disease management; discuss clinical data on EGFR-targeted agents and plans for advancing their development over the next 2-3 years; and assess the safety and efficacy of EGFR-targeted agents in the treatment of lung cancer. The program was supported by educational grants from industry.
The conference proceedings were published as a peer-reviewed CME supplement to Clinical Cancer Research Vol 12. No 14. July 15 2006.
Journal Website
(subscription may be required to access full journal supplement)
